{"title": "NewsRamp Curated News Feed for Science", "description": "NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.", "site_url": "https://www.newsramp.com", "display_name": "NewsRamp.com", "next_page": "https://feeds.newsramp.net/tldr/newsramp/moderated/10/2/science.json", "instructions": "Fine tune the feed as follows /tldr/category/newsramp/en/all/20/1/science.json /tldr/category/en/[all/moderated]/[records per page up to 100]/[page number]/science.json - Available Language Codes English=en", "prev_page": "", "current_page": 1, "total_records": 2373, "total_pages": 238, "image_url": "https://newsramp.com/light-logo.svg", "language": "en", "ttl": 10, "news": [{"feed_item_id": 30962, "prhash_id": "abe742c44eef0c96b49480f91850b884", "headline": "Generation Uranium Advances High-Impact Targets for 2026 Yath Drill Program", "content": "        <article>        <h1>Generation Uranium Advances High-Impact Targets for 2026 Yath Drill Program</h1>        <img src='https://cdn.newsramp.app/banners/business-corporate-4.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Generation Uranium Advances High-Impact Targets for 2026 Yath Drill Program'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Generation Uranium's advanced targeting positions it for potential uranium discovery in 2026, offering investors early entry into a promising district with proven adjacent success.</li>            <li>Generation Uranium integrated modern geophysics with historic datasets and structural analysis to define multiple high-impact drill targets at its Yath Uranium Project.</li>            <li>This uranium exploration contributes to future clean nuclear energy supply, supporting global decarbonization efforts through responsible resource development.</li>            <li>Generation Uranium identified untested high-potential zones using MobileMT surveys and is targeting structural convergence zones known for major uranium discoveries.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development matters because it represents a significant step forward in uranium exploration at a time when global demand for clean nuclear energy is increasing. As countries worldwide seek to reduce carbon emissions and transition to sustainable energy sources, uranium remains a critical component of the nuclear power equation. Generation Uranium's progress in the Angilak district\u2014one of Canada's most active uranium camps\u2014could potentially contribute to future global supply. The company's application of proven discovery models from neighboring successes increases the likelihood of meaningful discoveries, which could impact energy security, create economic opportunities in Nunavut, and provide investors with exposure to a strategically important commodity. Successful exploration could also validate the geological potential of the region, potentially attracting further investment and development in Canada's uranium sector.</p>        <h2>Summary</h2>        <p><p>Generation Uranium Inc. (TSXV: GEN, OTCQB: GENRF, FRA: W85) has announced significant progress in defining high-impact drill targets at its 100%-owned Yath Uranium Project in Nunavut's Angilak district, positioning the company for a transformative 2026 exploration program. Following an extensive winter technical review that integrated modern geophysics, historic datasets, and structural analysis, the company has identified multiple compelling drill targets across structurally controlled uranium corridors. Key players include CEO Michael Collins, who has approved the scientific disclosure, and neighboring operator Atha Energy, whose successful discovery model at the adjacent Angilak Project is being directly applied to Generation's exploration strategy. The company is leveraging proven methodologies from one of Canada's most active uranium districts, where Atha Energy has recently made high-grade discoveries and launched a $63 million exploration program.</p><p>Generation's technical advancements include the integration of the Expert Geophysics MobileMT ('MMT') survey flown in 2024 with emerging discovery models, sophisticated inversion modeling using historic datasets like AeroTEM (2008) TDEM and Fugro DIGHEM (2011) FDEM, and the identification of an uns surveyed high-potential zone that requires MMT expansion. The company has defined several priority drill target areas including the VGR Trend (with planned seismic survey), BOG Zone along a northeast mineralized trend, Fog & IM-6 Targets along east-west structural corridors, and high-priority zones like Embryo, Lucky Break, MP-25, and Boulder Lake located at the convergence of key structural trends. These structural convergence zones represent critical controls observed in major uranium systems and form the focus for discovery-driven drilling.</p><p>The upcoming 2026 field season is expected to be catalyst-rich, featuring targeted seismic surveys, structural reinterpretation, completion of MMT coverage, and drill testing of priority zones. Generation is currently in advanced discussions with Expert Geophysics to complete the MMT survey coverage that was interrupted by adverse weather conditions in 2024, which would unlock a previously untested and highly prospective portion of the property. CEO Michael Collins emphasized that the company enters 2026 with 'a significantly strengthened technical understanding of the Yath Project and a pipeline of highly compelling drill targets.' The strong district context, including historic uranium mineralization at the LAC 50 and RIB deposits south of Yath, supports the project's upside potential. For additional information, investors can visit the company's website at generationuranium.com, and further details are available through NEWMEDIAWIRE releases and the company's continuous disclosure filings on SEDAR+.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/abe742c44eef0c96b49480f91850b884.30962.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/abe742c44eef0c96b49480f91850b884.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/generation-uranium-defines-multiple-high-impact-drill-targets-at-yath-project-leveraging-proven-discovery-model-in-one-of-canada-s-hottest-uranium-districts-7086375/abe742c44eef0c96b49480f91850b884'>Generation Uranium Advances High-Impact Targets for 2026 Yath Drill Program.</a></p></div>        </article>    ", "published": "2026-04-16T12:00:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/abe742c44eef0c96b49480f91850b884.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/abe742c44eef0c96b49480f91850b884.webp", "enclosure": "https://cdn.newsramp.app/banners/business-corporate-4.jpg", "site_handle": "newmediawire", "seo_description": "Generation Uranium announces significant target definition at Yath Project, positioning for 2026 drill program in Nunavut's Angilak uranium district with multiple high-impact targets identified.", "newsramp_curated": "https://newsramp.com/curated-news/generation-uranium-advances-high-impact-targets-for-2026-yath-drill-program/abe742c44eef0c96b49480f91850b884"}, {"feed_item_id": 30960, "prhash_id": "fed52690b2507db047178ad58dc4aaea", "headline": "Fitzroy Minerals Reports High-Grade Copper Intercepts, Advances PFS in Chile", "content": "        <article>        <h1>Fitzroy Minerals Reports High-Grade Copper Intercepts, Advances PFS in Chile</h1>        <img src='https://cdn.newsramp.app/banners/business-corporate-4.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Fitzroy Minerals Reports High-Grade Copper Intercepts, Advances PFS in Chile'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Fitzroy Minerals' high-grade copper discoveries at Buen Retiro offer investors potential for significant returns as the company advances toward a Pre-Feasibility Study.</li>            <li>Fitzroy Minerals is conducting systematic definition drilling, metallurgical testing, and geophysical surveys to delineate Measured and Indicated Resources for their Heap Leach project.</li>            <li>Developing copper resources at Buen Retiro supports global electrification and sustainable energy transition by providing essential materials for renewable technologies.</li>            <li>Fitzroy Minerals discovered 92.5 meters of copper mineralization starting just 3.5 meters below surface, with sections grading up to 0.90% copper.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it signals tangible progress in developing a new copper resource in Chile, a critical global supplier of the metal essential for electrification and renewable energy infrastructure. The high-grade intercepts and systematic advancement toward a Pre-Feasibility Study reduce technical risk and enhance the project's economic viability. For investors and the mining sector, successful development could contribute to future copper supply, supporting the global transition to clean energy amid growing demand and potential shortages. The use of advanced geophysical surveys and detailed metallurgical testing also demonstrates modern, efficient exploration approaches that could set a precedent for future discoveries.</p>        <h2>Summary</h2>        <p><p>Fitzroy Minerals Inc. (TSXV: FTZ, OTCQX: FTZFF, FSE: C3Y) has announced significant progress at its Buen Retiro Copper Project in Copiapo, Chile, with promising definition drilling results, the commencement of metallurgical test work for a Pre-Feasibility Study (PFS), and the completion of a major geophysical survey. The company, led by President and CEO Merlin Marr-Johnson, reported that drill hole BRT-DDH048 intersected 92.5 meters at 0.53% copper from just 3.5 meters depth, including a higher-grade zone of 46.0 meters at 0.82% copper. Similarly, drill hole BRT-DDH049 returned 83.0 meters at 0.57% copper, with 43.0 meters at 0.90% copper. These results are part of a 32-hole, 5,143-meter definition drilling program using two rigs to delineate a maiden mineral resource estimate, with the aim of completing this phase by May before reallocating rigs for further exploration and geotechnical work.</p><p>The core message from management emphasizes the rapid advancement of resource definition, with many samples exceeding laboratory limits for standard assay methods, indicating 'plenty of copper in the system.' A key milestone is the start of metallurgical test work at SGS Laboratories on a 2,900-kilogram representative sample, which will evaluate copper extraction kinetics, acid consumption, and heap leach performance across three defined geo-metallurgical domains: a higher-grade oxide domain (\u22650.5% Cu), a lower-grade oxide domain (0.10-0.5% Cu), and a mixed supergene transition domain. Concurrently, Fleet Space Technologies has completed a passive seismic Ambient Noise Tomography (ANT) geophysical survey over a 5 km x 5 km area, with data processing underway to aid in the hunt for major sulphide discoveries. The company's strategy involves leveraging potential cash flow from a heap leach operation to fund further exploration in Chile with minimal dilution.</p><p>Additional details highlight the company's rigorous quality assurance procedures, with samples analyzed at ALS-Patagonia laboratory and oversight by independent Qualified Person Dr. Scott Jobin-Bevans. The drilling has revealed a consistent mineralized package approximately 80-90 meters thick in the southwest area, dipping steeply to the east-northeast. Fitzroy Minerals, which also holds projects in Argentina and Canada, is focused on copper exploration and development in the Americas. For more information, readers can visit the company's website at www.fitzroyminerals.com or view the original release on www.newmediawire.com, which provides further context on these developments as the company moves toward its maiden resource estimate and economic study.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/fed52690b2507db047178ad58dc4aaea.30960.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/fed52690b2507db047178ad58dc4aaea.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/fitzroy-minerals-continues-with-2-rig-definition-drilling-intercepting-92-5-metre-at-0-53-copper-from-3-5-metre-as-it-moves-toward-a-maiden-mineral-resource-estimate-and-initial-economic-study-at-the-buen-retiro-copper-project-chile-7086374/fed52690b2507db047178ad58dc4aaea'>Fitzroy Minerals Reports High-Grade Copper Intercepts, Advances PFS in Chile.</a></p></div>        </article>    ", "published": "2026-04-16T11:00:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/fed52690b2507db047178ad58dc4aaea.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/fed52690b2507db047178ad58dc4aaea.webp", "enclosure": "https://cdn.newsramp.app/banners/business-corporate-4.jpg", "site_handle": "newmediawire", "seo_description": "Fitzroy Minerals announces high-grade copper drilling results at Buen Retiro, Chile, with 92.5m at 0.53% Cu, advancing metallurgical work and geophysical surveys for Pre-Feasibility Study.", "newsramp_curated": "https://newsramp.com/curated-news/fitzroy-minerals-reports-high-grade-copper-intercepts-advances-pfs-in-chile/fed52690b2507db047178ad58dc4aaea"}, {"feed_item_id": 30952, "prhash_id": "293fa383bc5a76e31f9db978e6ed4246", "headline": "GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial in 2026", "content": "        <article>        <h1>GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial in 2026</h1>        <img src='https://cdn.newsramp.app/banners/business-corporate-7.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial in 2026'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>GeoVax's GEO-MVA vaccine offers a competitive advantage by addressing global supply constraints for orthopoxvirus vaccines, potentially capturing market share through expedited regulatory pathways and strategic partnerships.</li>            <li>GeoVax plans to initiate a pivotal Phase 3 immuno-bridging study for GEO-MVA in late 2026, following regulatory alignment with EMA and completion of cGMP manufacturing for clinical-grade vaccine.</li>            <li>GEO-MVA aims to improve global public health by providing a critically needed vaccine supply for mpox and smallpox, enhancing biosecurity preparedness and protecting vulnerable populations worldwide.</li>            <li>GeoVax's GEO-MVA vaccine uses Modified Vaccinia Ankara technology to target both mpox and smallpox, representing a dual-purpose solution to address recurring outbreaks and depleted government stockpiles.</li>        </ul>        <h2>Why it Matters</h2>        <p>This development matters because it addresses a critical gap in global vaccine supply for orthopoxviruses like mpox and smallpox, which pose ongoing public health threats. Recent outbreaks have depleted government stockpiles, highlighting vulnerabilities in pandemic preparedness. GEO-MVA's accelerated regulatory pathway could provide a much-needed domestic manufacturing alternative, reducing reliance on single foreign sources and enhancing biosecurity. For populations at risk\u2014including healthcare workers, immunocompromised individuals, and those in outbreak regions\u2014this vaccine represents a potential safeguard against future epidemics. Furthermore, successful development would strengthen global health infrastructure, offering a tool for rapid response to emerging viral strains and supporting international preparedness frameworks.</p>        <h2>Summary</h2>        <p><p>GeoVax Labs, a clinical-stage biotechnology company, has announced its 2025 financial results alongside significant progress on its lead vaccine candidate, GEO-MVA. The company's primary focus is advancing this Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox, with plans to initiate a pivotal Phase 3 immuno-bridging study in the second half of 2026. This development follows regulatory alignment with the European Medicines Agency (EMA) that supports an accelerated pathway, potentially bypassing earlier trial phases. CEO David Dodd emphasized that GEO-MVA addresses critical global supply constraints for orthopoxvirus vaccines, depleted government stockpiles, and the need for diversified domestic manufacturing to enhance public health preparedness and biosecurity.</p><p>Beyond its priority program, GeoVax continues to advance a diversified pipeline including GEO-CM04S1, a next-generation COVID-19 vaccine showing promising interim results in immunocompromised populations, and Gedeptin\u00ae, an oncology therapy for head and neck cancer that has entered into an exclusive license agreement with Emory University. The company reported a net loss of $21.5 million for 2025, with decreased research expenses following the termination of a BARDA contract, and maintains a cash position of $3.1 million. For more information, visit www.geovax.com, where investors and stakeholders can find detailed corporate updates and forward-looking statements about these clinical developments.</p><p>The company's strategic positioning at the intersection of recurring mpox outbreaks, evolving viral strains, and policy-driven demand for vaccine supply diversification makes GEO-MVA potentially central to global orthopoxvirus preparedness. With manufacturing readiness established through completed cGMP production and fill-finish operations, GeoVax is actively engaging international regulatory and governmental stakeholders to align with procurement frameworks. This comprehensive approach underscores the company's commitment to addressing critical medical needs while maximizing long-term value, as detailed in their recent financial disclosures and operational highlights that signal important milestones toward potential regulatory approval and commercialization.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/293fa383bc5a76e31f9db978e6ed4246.30952.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/293fa383bc5a76e31f9db978e6ed4246.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/geovax-reports-2025-year-end-financial-results-and-provides-business-update-7086367/293fa383bc5a76e31f9db978e6ed4246'>GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial in 2026.</a></p></div>        </article>    ", "published": "2026-04-15T20:04:20+00:00", "audio_release": "https://cdn.newsramp.net/audio/293fa383bc5a76e31f9db978e6ed4246.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/293fa383bc5a76e31f9db978e6ed4246.webp", "enclosure": "https://cdn.newsramp.app/banners/business-corporate-7.jpg", "site_handle": "newmediawire", "seo_description": "GeoVax Labs announces Phase 3 trial plans for GEO-MVA mpox/smallpox vaccine in 2026, addressing global supply constraints with accelerated regulatory pathway and manufacturing readiness.", "newsramp_curated": "https://newsramp.com/curated-news/geovax-advances-mpox-smallpox-vaccine-toward-phase-3-trial-in-2026/293fa383bc5a76e31f9db978e6ed4246"}, {"feed_item_id": 30944, "prhash_id": "f3b853b90edddc735ea005a6f283892b", "headline": "Lode Gold Accelerates Fremont Project with Aggressive Drill Plan Toward Feasibility", "content": "        <article>        <h1>Lode Gold Accelerates Fremont Project with Aggressive Drill Plan Toward Feasibility</h1>        <img src='https://cdn.newsramp.app/banners/science-1.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Lode Gold Accelerates Fremont Project with Aggressive Drill Plan Toward Feasibility'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Lode Gold's accelerated exploration strategy at Fremont offers investors early access to a high-grade gold project with potential for rapid development and resource expansion.</li>            <li>Lode Gold will conduct 3,500 meters of drilling in 2026 for a Preliminary Feasibility Study, followed by 7,800 meters in 2028 for a Feasibility Study, focusing on bulk underground mining.</li>            <li>This project could revitalize local economies through job creation and responsible resource development while utilizing modern mining techniques for sustainable gold extraction.</li>            <li>The Fremont project contains gold deposits with remarkable geological continuity, where only 2 of 7 known deposits have been mined historically at an average grade of 10.7 g/t.</li>        </ul>        <h2>Why it Matters</h2>        <p>This announcement signals a major step in revitalizing a historic California gold district with modern mining techniques. For investors and the mining sector, it represents a potentially de-risked path to a new, scalable gold production source in a stable jurisdiction. The project's location in an Opportunity Zone with tax incentives and its brownfield status could lower development costs and timelines. Success here could contribute to domestic gold supply, create local jobs in Mariposa County, and demonstrate the viability of redeveloping legacy mining projects with advanced bulk underground methods, influencing investment trends in junior mining companies.</p>        <h2>Summary</h2>        <p><p>Lode Gold Resources Inc. (TSX.V: LOD | LODFF:OTCQB) has announced an aggressive acceleration of its Fremont Gold Project in Mariposa County, California, aiming to fast-track the historic property toward production through a clear two-phase drilling strategy. The company, led by CEO Wendy T. Chan, plans a 3,500-meter drill program in 2026 to support a Preliminary Feasibility Study (PFS) targeted for completion by Q2 2027, followed by a massive 7,800-meter underground drill program in 2028 to advance a full Feasibility Study (FS) by 2029. This revised development approach focuses on bulk underground mining, capitalizing on the project's strong geological continuity along the Mother Lode structural corridor and a growing Mineral Resource Estimate (MRE) that already boasts approximately 3 million ounces of gold over just an 800-meter segment of a broader 4-kilometer trend.</p><p>The 2026 program is strategically designed to de-risk the project and includes 1,400 meters of metallurgical and geotechnical drilling, 600 meters of hydrological and infill drilling in the high-grade Pine Tree - Josephine area (historically mined at 10.7 g/t), and 1,500 meters of step-out exploration in the Chicken Gulch area. Technical leaders, including Jon Hill, Technical Committee Chair, and Bill Fisher of the Technical Advisory Board, emphasize Fremont's unique position, with mineralization characteristics ideal for bulk mining and the potential to advance a PFS within an ambitious 15-month timeframe due to an extensive historical database and easy-to-upgrade resource base. The subsequent 2028 FS program will utilize two parallel exploration ramps, each about 2,200 meters long, which will later be incorporated into the mining infrastructure, supporting a phased transition to production.</p><p>The Fremont project is a significant brownfield asset with a rich history, having last seen comparable technical advancement in 1986. It sits on over 3,000 acres of 100% owned private and patented land within an Opportunity Zone, offering special tax incentives. A Preliminary Economic Assessment (PEA) was completed in 2023, and an MRE was updated in 2025, revealing that 92% of the ounces remain unmined. The company's strategy reflects improved geological understanding and favorable market conditions, positioning Fremont as a scalable underground project with a clear path to unlocking its full value. Lode Gold also holds the Dingman Property in Ontario, Canada, but the current focus and accelerated capital are squarely on advancing the flagship Fremont Gold Project toward development.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/f3b853b90edddc735ea005a6f283892b.30944.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/f3b853b90edddc735ea005a6f283892b.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/lode-gold-fremont-gold-mine-fast-tracks-development-with-3-500-m-for-preliminary-feasibility-study-7086360/f3b853b90edddc735ea005a6f283892b'>Lode Gold Accelerates Fremont Project with Aggressive Drill Plan Toward Feasibility.</a></p></div>        </article>    ", "published": "2026-04-15T17:30:25+00:00", "audio_release": "https://cdn.newsramp.net/audio/f3b853b90edddc735ea005a6f283892b.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/f3b853b90edddc735ea005a6f283892b.webp", "enclosure": "https://cdn.newsramp.app/banners/science-1.jpg", "site_handle": "newmediawire", "seo_description": "Lode Gold unveils accelerated drill strategy for its Fremont Gold Project in California, targeting PFS by 2027 and FS by 2029 to fast-track the bulk underground mine toward production.", "newsramp_curated": "https://newsramp.com/curated-news/lode-gold-accelerates-fremont-project-with-aggressive-drill-plan-toward-feasibility/f3b853b90edddc735ea005a6f283892b"}, {"feed_item_id": 30925, "prhash_id": "b53c1abe1d870e97785c31aec2c6960a", "headline": "Canadian Scientists Discover Brain Cells Fuel Deadly Glioblastoma Tumors", "content": "        <article>        <h1>Canadian Scientists Discover Brain Cells Fuel Deadly Glioblastoma Tumors</h1>        <img src='https://cdn.newsramp.app/banners/science-7.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Canadian Scientists Discover Brain Cells Fuel Deadly Glioblastoma Tumors'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>CNS Pharmaceuticals Inc. gains a competitive edge by targeting newly discovered glioblastoma-supporting cells, potentially accelerating effective treatment development.</li>            <li>Canadian scientists found that passive brain cells actively fuel glioblastoma growth through signaling, revealing a new therapeutic target for companies like CNS Pharmaceuticals Inc.</li>            <li>This discovery offers hope for better glioblastoma treatments, potentially improving survival rates and quality of life for patients worldwide.</li>            <li>Brain cells once thought passive secretly fuel deadly cancer growth, a surprising finding that could revolutionize glioblastoma treatment approaches.</li>        </ul>        <h2>Why it Matters</h2>        <p>This discovery fundamentally changes our understanding of glioblastoma biology by revealing that non-cancerous brain cells actively contribute to tumor growth rather than just providing passive support. For patients facing this aggressive brain cancer with limited treatment options, this finding opens new therapeutic avenues that could target these supportive cells alongside cancer cells themselves. The research could lead to more effective combination therapies and potentially improve survival rates for a disease that currently has a devastating prognosis. For investors and the medical community, it highlights the importance of continued research investment and the potential for companies like CNS Pharmaceuticals to develop novel treatments based on these biological insights.</p>        <h2>Summary</h2>        <p><p>Canadian scientists have made an unexpected finding about glioblastoma, one of the deadliest and hardest-to-treat forms of brain cancer, revealing that cells previously considered passive support structures in healthy brain tissue actually actively fuel tumor growth through signaling that boosts cancer cell function. This discovery challenges long-held assumptions about brain cancer biology and opens new avenues for therapeutic intervention against a disease notorious for its aggressive nature and limited treatment options.</p><p>The rush to develop effective therapies against glioblastoma is gaining momentum, with entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) working tirelessly to bring to market new treatments that move the dial in the fight against this deadly type of brain cancer. As more insights about what drives tumor progression emerge, companies like CNS Pharmaceuticals are positioned to translate these scientific breakthroughs into clinical applications, potentially offering hope where traditional approaches have fallen short.</p><p>This news is presented by TinyGems, a specialized communications platform within the Dynamic Brand Portfolio at IBN that focuses on innovative small-cap and mid-cap companies with bright futures and huge potential. Through services like article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution via IBN to millions of followers, TinyGems helps companies reach a wide audience of investors, influencers, and the general public. The platform's comprehensive corporate communications solutions ensure that important developments in fields like oncology research receive the visibility they deserve, connecting scientific progress with investment opportunities and public awareness.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/b53c1abe1d870e97785c31aec2c6960a.30925.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/b53c1abe1d870e97785c31aec2c6960a.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//b53c1abe1d870e97785c31aec2c6960a'>Canadian Scientists Discover Brain Cells Fuel Deadly Glioblastoma Tumors.</a></p></div>        </article>    ", "published": "2026-04-15T14:05:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/b53c1abe1d870e97785c31aec2c6960a.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/b53c1abe1d870e97785c31aec2c6960a.webp", "enclosure": "https://cdn.newsramp.app/banners/science-7.jpg", "site_handle": "ibn", "seo_description": "Canadian scientists discover brain cells actively fuel glioblastoma growth, challenging cancer biology. CNS Pharmaceuticals develops new treatments as TinyGems reports on this breakthrough finding.", "newsramp_curated": "https://newsramp.com/curated-news/canadian-scientists-discover-brain-cells-fuel-deadly-glioblastoma-tumors/b53c1abe1d870e97785c31aec2c6960a"}, {"feed_item_id": 30936, "prhash_id": "3585bbbde487ee0d4aaca5bc5f07b256", "headline": "Soligenix Gains Analytical Validation as Pipeline Progress Drives Forward Outlook", "content": "        <article>        <h1>Soligenix Gains Analytical Validation as Pipeline Progress Drives Forward Outlook</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-6.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Soligenix Gains Analytical Validation as Pipeline Progress Drives Forward Outlook'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Soligenix's strong interim FLASH2 data and upcoming catalysts position investors for potential gains as the company advances its phase 3 trial.</li>            <li>Zacks Research analyzed Soligenix's pipeline progress, including phase 3 FLASH2 trial interim data trends and upcoming milestones, to assess valuation potential.</li>            <li>Soligenix's HyBryte treatment for cutaneous T-cell lymphoma could improve patient outcomes, representing meaningful progress in cancer therapy development.</li>            <li>A Zacks analysis highlights Soligenix's promising FLASH2 study data and pipeline depth, offering insight into this emerging biotech company's strategy.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because independent research validation from respected firms like Zacks can significantly influence investor confidence and market perception of emerging biotech companies. For patients with cutaneous T-cell lymphoma, the progress of HyBryte\u2122 through phase 3 trials represents potential new treatment options. For investors, the detailed analysis provides crucial insights into valuation drivers and upcoming catalysts that could impact stock performance. In the competitive biotech sector, such third-party validation helps distinguish promising companies from the crowded field, potentially affecting funding opportunities and partnership discussions.</p>        <h2>Summary</h2>        <p><p>A recent analysis from Zacks Small-Cap Research provides a comprehensive outlook on Soligenix (NASDAQ: SNGX), highlighting the company's promising pipeline and upcoming milestones that position it for a potentially eventful period ahead. The report emphasizes the strength of interim data trends from the phase 3 FLASH2 clinical trial evaluating HyBryte\u2122 for the treatment of cutaneous T-cell lymphoma, with an interim analysis expected soon. This independent research coverage brings together clinical progress, financial positioning, and forward-looking catalysts into a cohesive perspective that reinforces the credibility of Soligenix's development strategy.</p><p>Beyond the FLASH2 study, the analysis underscores additional clinical and scientific developments that contribute to the depth of Soligenix's pipeline, offering investors detailed insights into the company's valuation potential. The report serves as analytical validation for Soligenix as its pipeline progress drives a forward outlook, with key milestones outlined that could significantly impact the company's trajectory. For those interested in following the latest developments, the company maintains an active newsroom where updates are regularly posted.</p><p>BioMedWire, the specialized communications platform publishing this content, operates as part of the Dynamic Brand Portfolio within IBN, delivering comprehensive distribution solutions across financial and biotech sectors. The platform provides enhanced press release services, social media distribution to millions of followers, and editorial syndication to over 5,000 outlets, ensuring that breaking news and insightful content about companies like Soligenix reaches a wide audience of investors, journalists, and the general public.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/3585bbbde487ee0d4aaca5bc5f07b256.30936.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/3585bbbde487ee0d4aaca5bc5f07b256.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//3585bbbde487ee0d4aaca5bc5f07b256'>Soligenix Gains Analytical Validation as Pipeline Progress Drives Forward Outlook.</a></p></div>        </article>    ", "published": "2026-04-15T13:05:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/3585bbbde487ee0d4aaca5bc5f07b256.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/3585bbbde487ee0d4aaca5bc5f07b256.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-6.jpg", "site_handle": "ibn", "seo_description": "Zacks analysis validates Soligenix's pipeline progress, highlighting HyBryte\u2122 phase 3 trial for cutaneous T-cell lymphoma and upcoming milestones driving forward outlook for investors.", "newsramp_curated": "https://newsramp.com/curated-news/soligenix-gains-analytical-validation-as-pipeline-progress-drives-forward-outlook/3585bbbde487ee0d4aaca5bc5f07b256"}, {"feed_item_id": 30911, "prhash_id": "537e9c66edce89d25200089f820659f3", "headline": "NeuroOne and University of Minnesota Pioneer sEEG-Based Epilepsy Drug Delivery", "content": "        <article>        <h1>NeuroOne and University of Minnesota Pioneer sEEG-Based Epilepsy Drug Delivery</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-7.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='NeuroOne and University of Minnesota Pioneer sEEG-Based Epilepsy Drug Delivery'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>NeuroOne's collaboration with the University of Minnesota could give the company a first-mover advantage in developing precise, brain-targeted epilepsy therapies that reduce systemic side effects.</li>            <li>The study uses NeuroOne's sEEG platform to deliver novel therapeutics directly into specific brain regions, aiming to improve efficacy while lowering toxicity through localized intracerebral infusion.</li>            <li>This research could lead to more precise, individualized epilepsy treatments that minimize side effects, offering patients better outcomes and improved quality of life through targeted brain therapy.</li>            <li>Scientists are testing ultra-thin electrodes to deliver drugs directly into seizure networks, potentially creating a new era of precision brain therapy for epilepsy patients.</li>        </ul>        <h2>Why it Matters</h2>        <p>This collaboration matters because it addresses a critical gap in epilepsy treatment by focusing on localized drug delivery, which could significantly reduce systemic side effects and improve precision for patients. Epilepsy affects millions worldwide, and current treatments often involve medications with broad impacts on the body, leading to adverse reactions and limited efficacy. By targeting specific brain regions involved in seizures, this approach has the potential to enhance therapeutic outcomes, minimize toxicity, and offer more personalized care. If successful, it could pave the way for new standards in neurological therapies, benefiting patients with drug-resistant epilepsy and reducing healthcare burdens through fewer hospitalizations and improved quality of life. This innovation aligns with broader trends in precision medicine, highlighting how advanced medical technologies can transform chronic disease management.</p>        <h2>Summary</h2>        <p><p>NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company specializing in neurological disorder treatments, has announced a groundbreaking collaboration with the University of Minnesota Medical School's Department of Neurology's Division of Epilepsy. This partnership aims to advance a study evaluating next-generation epilepsy therapies using NeuroOne's innovative sEEG-based platform for localized drug delivery. The program is led by Dr. Sandipan Pati, Professor and Epilepsy Division Director, who is at the forefront of epilepsy care and research, bringing academic expertise and clinical insight to this pioneering initiative.</p><p>The core focus of this collaboration is on testing novel therapeutics delivered directly into specific brain regions involved in sustaining seizures, with the goal of improving clinical efficacy while reducing systemic toxicity and off-target effects. The study is expected to begin with large animal models and, if primary objectives are met, progress to human studies shortly thereafter. Dr. Pati emphasized that localized intracerebral delivery represents an important emerging direction for enhancing precision in epilepsy treatment, potentially minimizing systemic side effects and offering more individualized therapies for patients. NeuroOne's President and CEO, Dave Rosa, highlighted the University of Minnesota's leadership in next-generation epilepsy research, expressing optimism that this collaboration could support the development of a first-in-human study utilizing their technology, which might redefine seizure care and establish a new era of precision brain-directed therapy.</p><p>NeuroOne's technology platform includes FDA-cleared products such as Evo\u00ae Cortical Electrodes, Evo\u00ae sEEG Electrodes, and the OneRF\u00ae Ablation System, which are designed to reduce hospitalizations, lower costs, and improve patient outcomes through combination diagnostic and therapeutic functions. The company is actively engaged in research and development for drug delivery and spinal cord stimulation programs, with more information available at nmtc1.com. This news release was distributed via NEWMEDIAWIRE, and the original release can be viewed on www.newmediawire.com, underscoring the significance of this collaboration in the medical technology and epilepsy treatment fields. The forward-looking statements in the release caution about potential risks and uncertainties, but the overall message points to a promising step toward transformative neurological care.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/537e9c66edce89d25200089f820659f3.30911.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/537e9c66edce89d25200089f820659f3.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/neuroone-r-advances-brain-drug-delivery-platform-through-collaboration-with-university-of-minnesota-7086352/537e9c66edce89d25200089f820659f3'>NeuroOne and University of Minnesota Pioneer sEEG-Based Epilepsy Drug Delivery.</a></p></div>        </article>    ", "published": "2026-04-15T12:30:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/537e9c66edce89d25200089f820659f3.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/537e9c66edce89d25200089f820659f3.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-7.jpg", "site_handle": "newmediawire", "seo_description": "NeuroOne partners with University of Minnesota to advance sEEG-based drug delivery for epilepsy, aiming to improve precision and reduce side effects in seizure treatment.", "newsramp_curated": "https://newsramp.com/curated-news/neuroone-and-university-of-minnesota-pioneer-seeg-based-epilepsy-drug-delivery/537e9c66edce89d25200089f820659f3"}, {"feed_item_id": 30906, "prhash_id": "658324044295020760a6fd3722ecf6c7", "headline": "Loneliness Linked to 19% Higher Risk of Degenerative Heart Valve Disease", "content": "        <article>        <h1>Loneliness Linked to 19% Higher Risk of Degenerative Heart Valve Disease</h1>        <img src='https://cdn.newsramp.app/banners/health-wellness-1.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Loneliness Linked to 19% Higher Risk of Degenerative Heart Valve Disease'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Addressing loneliness could provide a health advantage by reducing degenerative heart valve disease risk by up to 23%, potentially delaying costly surgical interventions.</li>            <li>A 14-year study of 463,000 UK Biobank participants found loneliness increases degenerative heart valve disease risk by 19-23%, independent of genetics and traditional risk factors.</li>            <li>Recognizing loneliness as a modifiable health risk could improve cardiovascular outcomes and reduce the societal burden of valvular heart disease through better social connection.</li>            <li>Loneliness, not social isolation, increases heart valve disease risk by 19-23%, with unhealthy lifestyle habits explaining part of this surprising connection.</li>        </ul>        <h2>Why it Matters</h2>        <p>This research matters because it identifies loneliness as a significant, potentially modifiable risk factor for a serious heart condition that affects millions, particularly as populations age. Unlike social isolation, which involves objective measures like living alone, loneliness is a subjective feeling of lacking meaningful connections\u2014something that can occur even in crowded rooms or with many online 'friends.' The study shows that chronic loneliness acts as a biological stressor, increasing the risk of degenerative heart valve disease by 19%, with even higher risks for specific valve problems like aortic stenosis and mitral regurgitation. This has direct implications for public health: by recognizing and addressing loneliness, healthcare providers and individuals could potentially delay disease progression, reduce the need for invasive surgeries like valve replacements, and improve overall quality of life. In an era where social disconnectedness is rising despite digital connectivity, this finding underscores that genuine human connection is not just emotionally fulfilling but physiologically protective, offering a new avenue for preventive cardiology that complements traditional lifestyle interventions.</p>        <h2>Summary</h2>        <p><p>Groundbreaking research published in the Journal of the American Heart Association reveals a significant link between loneliness and degenerative heart valve disease, a serious condition affecting the heart's valves. The study, led by researchers from The Second Xiangya Hospital in China and analyzing data from nearly 463,000 adults in the UK Biobank, found that adults reporting feelings of loneliness had a 19% higher risk of developing degenerative valvular heart disease over a median follow-up of nearly 14 years. This risk persisted even after accounting for traditional factors like genetics and lifestyle, with specific increases of 21% for aortic valve stenosis and 23% for mitral valve regurgitation. Notably, the research distinguished between loneliness\u2014a subjective feeling of lacking meaningful connection\u2014and objective social isolation, finding that isolation itself was not significantly associated with increased risk.</p><p>The study's key players include lead author Dr. Zhaowei Zhu and co-author Cheng Wei, who emphasize that loneliness may be an independent and modifiable risk factor for a disease that becomes more common with aging. American Heart Association expert Dr. Crystal Wiley Cene, who was not involved in the study but contributed context, stressed that loneliness is a biological stressor, not a moral failing. The research suggests unhealthy lifestyle habits like smoking and inactivity partially explain the link, but loneliness itself appears to exert a direct influence. With valvular heart disease accounting for over 440,000 U.S. deaths between 1999 and 2020, as noted in the American Heart Association's 2026 Heart Disease and Stroke Statistics Report, this finding highlights a critical public health concern.</p><p>This study represents one of the first large-scale examinations of loneliness's specific impact on valve health, building on prior AHA statements about social connection's role in cardiovascular health. The implications are profound: addressing loneliness could help delay disease progression, reduce the need for surgical interventions like valve replacement, and lessen the long-term clinical and economic burden. Researchers call for future studies to confirm findings in more diverse populations and explore biological mechanisms, while health professionals are encouraged to discuss loneliness as a legitimate health risk. The message is clear: meaningful social connections are vital for heart health, potentially offering a new pathway for prevention in an aging global population.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/658324044295020760a6fd3722ecf6c7.30906.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/658324044295020760a6fd3722ecf6c7.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://www.newmediawire.com'>NewMediaWire</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/newmediawire/en/loneliness-linked-to-increased-risk-of-degenerative-heart-valve-disease-7086351/658324044295020760a6fd3722ecf6c7'>Loneliness Linked to 19% Higher Risk of Degenerative Heart Valve Disease.</a></p></div>        </article>    ", "published": "2026-04-15T09:00:00+00:00", "audio_release": "https://cdn.newsramp.net/audio/658324044295020760a6fd3722ecf6c7.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/658324044295020760a6fd3722ecf6c7.webp", "enclosure": "https://cdn.newsramp.app/banners/health-wellness-1.jpg", "site_handle": "newmediawire", "seo_description": "New study finds loneliness increases risk of degenerative heart valve disease by 19%, even after accounting for genetics and lifestyle. Research highlights need to address social connection for heart health.", "newsramp_curated": "https://newsramp.com/curated-news/loneliness-linked-to-19-higher-risk-of-degenerative-heart-valve-disease/658324044295020760a6fd3722ecf6c7"}, {"feed_item_id": 30880, "prhash_id": "1bcfe49d99befddf2f9ad091fd30c967", "headline": "Powermax Minerals Reports Promising Rare Earth Element Discovery in BC", "content": "        <article>        <h1>Powermax Minerals Reports Promising Rare Earth Element Discovery in BC</h1>        <img src='https://cdn.newsramp.app/banners/science-1.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Powermax Minerals Reports Promising Rare Earth Element Discovery in BC'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Powermax Minerals' Cameron project shows high rare earth oxide values up to 2,840 ppm, offering investors early access to a potentially valuable North American resource.</li>            <li>Powermax Minerals conducted soil sampling at its 2,984-hectare Cameron project, identifying a one-kilometer corridor with TREO values averaging 340 ppm and peaking at 2,840 ppm.</li>            <li>Developing domestic rare earth sources like Powermax's Cameron project reduces reliance on foreign supply chains, supporting sustainable technology and energy independence.</li>            <li>A Canadian exploration company found rare earth mineralization in British Columbia pegmatites, with soil samples revealing concentrations historically linked to thorium-uranium deposits.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because rare earth elements are critical components in numerous modern technologies, including electric vehicles, wind turbines, smartphones, and defense systems. Currently, China dominates global rare earth production and processing, creating supply chain vulnerabilities for Western nations. Powermax Minerals' discovery of promising rare earth mineralization in British Columbia represents progress toward developing North American sources of these strategically important minerals. Successful development of domestic rare earth resources could reduce geopolitical dependencies, enhance supply chain security for clean energy technologies, and create economic opportunities in mining regions. For investors, this represents potential exposure to the growing critical minerals sector that's essential for the global transition to renewable energy and advanced technologies.</p>        <h2>Summary</h2>        <p><p>Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company, has announced promising early exploration results from its flagship Cameron Rare Earth Element Project in British Columbia. The company's recent soil and rock sampling programs have identified multiple areas of anomalous rare earth element mineralization associated with pegmatite systems, with Total Rare Earth Oxide (TREO) values ranging from approximately 135 parts per million to an impressive 2,840 ppm. The results outline a north-south trending corridor of elevated rare earth values extending for more than one kilometer, coinciding with mapped pegmatites and historically documented thorium-uranium mineralization in the Cameron (Jenkins) showing areas. The Cameron project, located roughly 40 kilometers south of Revelstoke along Highway 23 near the Columbia River, spans approximately 2,984 hectares within the Kamloops Mining Division, positioning Powermax Minerals at the forefront of North American rare earth element exploration.</p><p>The company's exploration success at the Cameron REE Property represents a significant development in the critical minerals sector, particularly given the strategic importance of rare earth elements for modern technologies. Powermax Minerals holds an option to acquire the Cameron property, which comprises three mineral claims, and has also optioned to acquire the Atikokan REE Property in Northwestern Ontario and the Pinard REE in Northern Ontario. Additionally, the company owns a 100% interest in the Ogden Bear Lodge Project in Crook County, Wyoming, demonstrating its diversified portfolio across North America. For investors and stakeholders interested in following the company's progress, the latest news and updates relating to PWMXF are available in the company's newsroom, providing transparency and timely information about these promising developments in the rare earth element exploration space.</p><p>The dissemination of this news is facilitated by InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio that provides advanced wire-grade press release syndication for private and public companies. This platform ensures that important developments like Powermax Minerals' exploration results reach a wide audience of investors, influencers, and industry professionals through article and editorial syndication to over 5,000 outlets, enhanced press release features, and comprehensive social media distribution. For those seeking more detailed information about the Cameron project findings, the full article discussing these promising early exploration results is available, offering deeper insights into the geological significance and potential of this rare earth element discovery in British Columbia.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/1bcfe49d99befddf2f9ad091fd30c967.30880.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/1bcfe49d99befddf2f9ad091fd30c967.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//1bcfe49d99befddf2f9ad091fd30c967'>Powermax Minerals Reports Promising Rare Earth Element Discovery in BC.</a></p></div>        </article>    ", "published": "2026-04-14T18:11:11+00:00", "audio_release": "https://cdn.newsramp.net/audio/1bcfe49d99befddf2f9ad091fd30c967.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/1bcfe49d99befddf2f9ad091fd30c967.webp", "enclosure": "https://cdn.newsramp.app/banners/science-1.jpg", "site_handle": "ibn", "seo_description": "Powermax Minerals announces promising rare earth element exploration results at its Cameron Project in British Columbia, with TREO values up to 2,840 ppm in soil samples.", "newsramp_curated": "https://newsramp.com/curated-news/powermax-minerals-reports-promising-rare-earth-element-discovery-in-bc/1bcfe49d99befddf2f9ad091fd30c967"}, {"feed_item_id": 30879, "prhash_id": "f526a300d1d3b3824dae3b5417a02fd3", "headline": "Soligenix Leverages Platform Science to Streamline Drug Development for Rare Diseases", "content": "        <article>        <h1>Soligenix Leverages Platform Science to Streamline Drug Development for Rare Diseases</h1>        <img src='https://cdn.newsramp.app/banners/business-corporate-4.jpg' style='width:80%; display: block; margin-left: auto; margin-right: auto; margin-top:1rem; margin-bottom:1rem;' alt='Soligenix Leverages Platform Science to Streamline Drug Development for Rare Diseases'/>        <h2>Key Takeaways (TLDR)</h2>        <ul>            <li>Soligenix's platform approach using synthetic hypericin gives it a strategic advantage in developing multiple treatments efficiently, potentially accelerating market entry and reducing development costs.</li>            <li>Soligenix leverages synthetic hypericin as a platform technology, streamlining development by using a shared mechanism across multiple dermatologic indications to reduce redundancy in preclinical and regulatory work.</li>            <li>Soligenix's platform-based drug development could bring faster, more affordable treatments for rare diseases like CTCL and psoriasis, improving patient outcomes and addressing unmet medical needs.</li>            <li>Soligenix uses synthetic hypericin as a versatile platform, treating conditions from CTCL to psoriasis while also developing vaccines with its heat stabilization technology.</li>        </ul>        <h2>Why it Matters</h2>        <p>This news matters because it showcases how platform-based drug development can accelerate treatments for rare and underserved diseases, potentially reducing costs and time-to-market. For patients with conditions like cutaneous T-cell lymphoma or psoriasis, Soligenix's approach could lead to more accessible and effective therapies. In the broader biopharmaceutical industry, this strategy enhances efficiency and risk management, encouraging innovation that addresses unmet medical needs. Additionally, the company's public health vaccine programs, supported by government agencies, highlight its role in pandemic preparedness and biodefense, impacting global health security. Investors and stakeholders should note this as a model for sustainable growth in biotech.</p>        <h2>Summary</h2>        <p><p>Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is featured in a recent article highlighting its strategic use of platform-based drug development. The company exemplifies this approach through its synthetic hypericin platform, which is being leveraged across multiple dermatologic indications. This strategy allows Soligenix to streamline development processes, reduce redundancy in preclinical work and regulatory documentation, and expand clinical impact efficiently. The article emphasizes how platform technology serves as a foundational system for developing multiple products, particularly in life sciences, offering significant risk management advantages in the competitive biotech landscape.</p><p>Soligenix's Specialized BioTherapeutics segment is advancing HyBryte\u2122 (SGX301), a novel photodynamic therapy using synthetic hypericin for treating cutaneous T-cell lymphoma (CTCL), with regulatory approvals sought following successful Phase 3 studies. The company is also expanding synthetic hypericin into psoriasis (SGX302) and developing first-in-class innate defense regulator technology for inflammatory diseases. Additionally, Soligenix's Public Health Solutions segment includes vaccine candidates for ricin toxin, filoviruses like Marburg and Ebola, and CiVax\u2122 for COVID-19 prevention, utilizing its proprietary ThermoVax\u00ae heat stabilization platform. These programs are supported by government grants and contracts from agencies such as NIAID, DTRA, and BARDA, underscoring their strategic importance.</p><p>The article was published by MissionIR, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides syndicated content and corporate communications solutions to enhance company visibility. MissionIR offers access to wire solutions via InvestorWire, editorial syndication to over 5,000 outlets, press release enhancement, and social media distribution through IBN's network. For more details, readers can visit the full article at https://ibn.fm/Sbnv0 or explore Soligenix's newsroom at https://ibn.fm/SNGX. This coverage illustrates how innovative biopharmaceutical companies like Soligenix are leveraging platform science to address unmet medical needs in rare diseases and public health, potentially transforming treatment paradigms and improving patient outcomes worldwide.</p></p>        <div><a href='https://newsramp.com/blockchain/txn_detail/f526a300d1d3b3824dae3b5417a02fd3.30879.bcuuid 'style='display: flex; align-items: flex-start;'><img src='https://cdn.newsramp.net/qrcode/f526a300d1d3b3824dae3b5417a02fd3.webp' class='newsramp-qrcode' style='width: 200px; max-width: 300px; margin-bottom: 25px;'  alt='Blockchain Registration, Verification & Enhancement provided by NewsRamp\u2122'/></a><p>This news story relied on content distributed by <a href='https://investorbrandnetwork.com'>InvestorBrandNetwork (IBN)</a>.  Blockchain Registration, Verification &amp; Enhancement provided by <a href='https://newsramp.com'>NewsRamp\u2122.</a> The source URL for this press release is <a href='https://newsramp.com/news/ibn/en//f526a300d1d3b3824dae3b5417a02fd3'>Soligenix Leverages Platform Science to Streamline Drug Development for Rare Diseases.</a></p></div>        </article>    ", "published": "2026-04-14T17:38:37+00:00", "audio_release": "https://cdn.newsramp.net/audio/f526a300d1d3b3824dae3b5417a02fd3.mp3", "blockchain_qrcode": "https://cdn.newsramp.net/qrcode/f526a300d1d3b3824dae3b5417a02fd3.webp", "enclosure": "https://cdn.newsramp.app/banners/business-corporate-4.jpg", "site_handle": "ibn", "seo_description": "Soligenix uses synthetic hypericin platform for multiple dermatologic treatments, streamlining drug development. Learn about its CTCL therapy, vaccine programs, and platform science advantages in biopharma innovation.", "newsramp_curated": "https://newsramp.com/curated-news/soligenix-leverages-platform-science-to-streamline-drug-development-for-rare-diseases/f526a300d1d3b3824dae3b5417a02fd3"}]}